Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Bolt Biotherapeutics (BOLT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: BOLT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.85% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.23M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 4 | Beta 0.93 | 52 Weeks Range 4.41 - 12.60 | Updated Date 12/28/2025 |
52 Weeks Range 4.41 - 12.60 | Updated Date 12/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -22.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -355.14% |
Management Effectiveness
Return on Assets (TTM) -32.04% | Return on Equity (TTM) -81.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1909620 | Price to Sales(TTM) 1.97 |
Enterprise Value 1909620 | Price to Sales(TTM) 1.97 | ||
Enterprise Value to Revenue 0.37 | Enterprise Value to EBITDA 0.93 | Shares Outstanding 1919441 | Shares Floating 1449101 |
Shares Outstanding 1919441 | Shares Floating 1449101 | ||
Percent Insiders 7.11 | Percent Institutions 40.26 |
Upturn AI SWOT
Bolt Biotherapeutics
Company Overview
History and Background
Bolt Biotherapeutics was founded in 2013 with the goal of developing novel cancer immunotherapies. The company has focused on creating a platform technology that enhances the body's immune response against cancer cells. Key milestones include the progression of its lead drug candidate through preclinical and early-stage clinical trials.
Core Business Areas
- Oncology Immuno-Oncology Platform: Bolt Biotherapeutics's core business revolves around its proprietary Boltbodyu2122 Bispecific TriNKET platform. This platform is designed to engage natural killer (NK) cells and T cells to recognize and kill cancer cells. The technology aims to overcome limitations of existing immunotherapies by activating innate and adaptive immune responses simultaneously.
Leadership and Structure
Bolt Biotherapeutics is led by a management team with experience in biotechnology and drug development. The organizational structure is typical for a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Description: BC-835 is Bolt Biotherapeutics's lead drug candidate, a bispecific antibody designed to target both tumor cells and immune cells, specifically NK cells and T cells. It is currently in clinical development for various solid tumors and hematologic malignancies. Competitors in this space include companies developing bispecific antibodies, CAR-NK therapies, and other immuno-oncology agents such as Amgen (Blincyto), Bristol Myers Squibb (Opdualag), and Regeneron Pharmaceuticals (Libtayo).
- Product Name 1: BC-835 (formerly B278)
Market Dynamics
Industry Overview
The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by the increasing understanding of the immune system's role in cancer and the demand for more effective and targeted cancer treatments. Significant investment is being made in novel therapeutic modalities.
Positioning
Bolt Biotherapeutics is positioning itself as a developer of next-generation immunotherapies with its unique Boltbodyu2122 platform. Its competitive advantage lies in its potential to activate both innate and adaptive immunity, potentially leading to broader efficacy and overcoming resistance mechanisms seen with other therapies.
Total Addressable Market (TAM)
The global oncology market is valued in the hundreds of billions of dollars and is projected to continue growing. The immuno-oncology segment is a substantial and expanding portion of this market. Bolt Biotherapeutics is positioned to capture a share of this TAM with its innovative approach to cancer treatment.
Upturn SWOT Analysis
Strengths
- Proprietary Boltbodyu2122 Bispecific TriNKET platform with potential for broad applicability.
- Focus on activating both innate and adaptive immunity.
- Experienced leadership team in biotechnology.
- Potential for differentiated efficacy and safety profile.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- High R&D costs and significant capital requirements.
- Limited commercialization infrastructure.
Opportunities
- Expanding the pipeline with new drug candidates based on the platform.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Addressing unmet needs in specific cancer types.
- Advancements in understanding cancer immunology.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Intense competition in the immuno-oncology space.
- Regulatory hurdles and delays.
- Funding challenges and market volatility.
Competitors and Market Share
Key Competitors
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Regeneron Pharmaceuticals (REGN)
- Genmab (GMAB)
- Merck & Co. (MRK)
Competitive Landscape
Bolt Biotherapeutics faces a highly competitive landscape dominated by large pharmaceutical companies with established immuno-oncology portfolios and significant R&D budgets. Bolt's advantage lies in its novel platform technology that could offer a differentiated approach compared to existing therapies. However, it must overcome the hurdles of clinical development and regulatory approval to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Bolt Biotherapeutics has been driven by the advancement of its pipeline and the securing of funding rounds to support its development activities.
Future Projections: Future growth projections are contingent on the successful progression of its drug candidates through clinical trials and eventual regulatory approval and commercialization. Analyst estimates would likely focus on the potential market penetration and revenue generation upon approval.
Recent Initiatives: Recent initiatives would include the initiation and progression of clinical trials for its lead candidates, potential collaborations, and efforts to secure further funding for its research and development programs.
Summary
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company with a promising immuno-oncology platform. Its strengths lie in its innovative technology and experienced team, but it faces significant risks associated with clinical development and a highly competitive market. Success hinges on positive clinical trial outcomes and securing adequate funding for its ambitious pipeline.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and investor presentations.
- Publicly available clinical trial databases.
- Biotechnology industry analysis reports.
- Financial news and market data providers.
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investing in clinical-stage biotechnology companies involves substantial risk, and investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bolt Biotherapeutics
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO, CFO, President, Secretary & Director Mr. William P. Quinn | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.boltbio.com |
Full time employees 40 | Website https://www.boltbio.com | ||
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.